What’s Propelling Biocryst Pharmaceuticals Incorporated (NASDAQ:BCRX) After Higher Shorts Reported?

December 8, 2017 - By Winifred Garcia

 What’s Propelling Biocryst Pharmaceuticals Incorporated (NASDAQ:BCRX) After Higher Shorts Reported?

Investors sentiment increased to 1.68 in 2017 Q2. Its up 0.18, from 1.5 in 2017Q1. It increased, as 15 investors sold BioCryst Pharmaceuticals, Inc. shares while 19 reduced holdings. 18 funds opened positions while 39 raised stakes. 66.24 million shares or 8.58% more from 61.01 million shares in 2017Q1 were reported.
Jpmorgan Chase holds 244,613 shares or 0% of its portfolio. Vanguard Group Inc Inc has invested 0% in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Meeder Asset Mgmt holds 156 shares. Bank & Trust Of America De invested in 16,034 shares or 0% of the stock. Janney Montgomery Scott Llc invested in 33,335 shares or 0% of the stock. 6.26 million are owned by Blackrock. Fincl Architects holds 0% or 30 shares in its portfolio. D E Shaw Co owns 0.02% invested in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for 2.09 million shares. The Ontario – Canada-based Royal Commercial Bank Of Canada has invested 0% in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). State Common Retirement Fund invested in 0% or 83,800 shares. Amer Grp holds 49,671 shares. 8,854 are owned by Bnp Paribas Arbitrage Sa. Moreover, Citigroup has 0% invested in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). 442 were reported by Sei. Barclays Public Ltd holds 162,716 shares or 0% of its portfolio.

The stock of Biocryst Pharmaceuticals Incorporated (NASDAQ:BCRX) registered an increase of 3.81% in short interest. BCRX’s total short interest was 11.09M shares in December as published by FINRA. Its up 3.81% from 10.69 million shares, reported previously. With 1.09 million shares average volume, it will take short sellers 10 days to cover their BCRX’s short positions. The short interest to Biocryst Pharmaceuticals Incorporated’s float is 21.19%.

The stock decreased 0.44% or $0.02 during the last trading session, reaching $4.57. About 663,349 shares traded. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has risen 75.08% since December 8, 2016 and is uptrending. It has outperformed by 58.38% the S&P500.

BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company has market cap of $449.71 million. The firm markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU. It currently has negative earnings. It also has various ongoing development programs, including BCX7353 and second generation oral inhibitors of plasma kallikrein for hereditary angioedema; and galidesivir, a broad spectrum viral RNA polymerase inhibitor that is indicated to treat filoviruses, as well as forodesine, an oral purine nucleoside phosphorylase inhibitor for use in oncology.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Ratings Coverage

Among 13 analysts covering BioCryst Pharmaceuticals (NASDAQ:BCRX), 11 have Buy rating, 0 Sell and 2 Hold. Therefore 85% are positive. BioCryst Pharmaceuticals has $16 highest and $2 lowest target. $7.33’s average target is 60.39% above currents $4.57 stock price. BioCryst Pharmaceuticals had 31 analyst reports since August 7, 2015 according to SRatingsIntel. PiperJaffray upgraded the stock to “Overweight” rating in Friday, August 12 report. The rating was downgraded by Bank of America to “Neutral” on Friday, October 9. The firm has “Buy” rating given on Thursday, February 16 by Ladenburg Thalmann. The rating was upgraded by J.P. Morgan on Wednesday, September 6 to “Buy”. Rodman & Renshaw maintained BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) on Tuesday, February 9 with “Buy” rating. The firm has “Hold” rating by Jefferies given on Friday, August 5. The company was initiated on Wednesday, September 9 by Jefferies. The firm earned “Buy” rating on Tuesday, August 8 by Noble Financial. The firm has “Buy” rating given on Tuesday, August 8 by H.C. Wainwright. Bank of America downgraded the shares of BCRX in report on Wednesday, November 11 to “Underperform” rating.

More news for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) were recently published by: Prnewswire.com, which released: “Biotech Stock Performance Review — BioCryst Pharma, Celgene, Exelixis, and Geron” on November 21, 2017. Seekingalpha.com‘s article titled: “BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse Q3 2017 Results …” and published on November 07, 2017 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.